K Tohyama
Overview
Explore the profile of K Tohyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
1200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thumkeo D, Katsura Y, Nishimura Y, Kanchanawong P, Tohyama K, Ishizaki T, et al.
Sci Adv
. 2020 Jan;
6(1):eaay2432.
PMID: 31911947
The mechanism by which the cytosolic protein Zap70 physically interacts with and phosphorylates its substrate, the transmembrane protein LAT, upon T cell receptor (TCR) stimulation remains largely obscure. In this...
2.
Tohyama K
Int J Lab Hematol
. 2018 May;
40 Suppl 1:120-125.
PMID: 29741254
The Japanese Society for Laboratory Hematology (JSLH) was launched in 2000 and has been developed by a mutual collaboration of hematologists, medical technologists, and the companies involved in hematological laboratory...
3.
Rhyasen G, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy J, Starczynowski D
Leukemia
. 2013 Dec;
28(5):1142-5.
PMID: 24326684
No abstract available.
4.
Fukuoka H, Sasaki J, Kamishina H, Sato R, Yasuda J, Katayama M, et al.
J Comp Pathol
. 2011 Oct;
147(1):37-41.
PMID: 22000037
A 6-year-old, neutered male Saint Bernard dog was presented with a 1-month history of ataxia, hypermetria and head tilt. High-field magnetic resonance imaging revealed a mass in the cerebellar vermis....
5.
Chiba K, Kawakami K, Tohyama K
Toxicol In Vitro
. 2010 Jul;
12(3):251-8.
PMID: 20654407
By combining three separate toxic assays, the neutral red (NR), MTT and crystal violet staining assays (CVS), we developed a convenient assay method, the NMC assay, in which the NR,...
6.
Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, et al.
Leukemia
. 2010 Feb;
24(4):748-55.
PMID: 20130600
Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the...
7.
Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T, et al.
Leukemia
. 2008 Aug;
22(10):1874-81.
PMID: 18668133
Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality...
8.
Satoh T, Okamoto S, Cui J, Watanabe Y, Furuta K, Suzuki M, et al.
Proc Natl Acad Sci U S A
. 2006 Jan;
103(3):768-73.
PMID: 16407140
Electrophilic neurite outgrowth-promoting prostaglandin (NEPP) compounds protect neurons from oxidative insults. At least part of the neuroprotective action of NEPPs lies in induction of hemeoxygenase-1 (HO-1), which, along with other...
9.
Li X, Pu Q, Shen W, Tohyama K, Deeg H
Zhonghua Xue Ye Xue Za Zhi
. 2005 Jan;
25(10):605-9.
PMID: 15634594
Objective: To investigate the biological changes in myelodysplastic syndromes (MDS) myeloid blast cell line MDS-L after different duration and concentration of As2O3/TRAIL (TNF related apoptosis inducing ligand) treatment. Methods: MDS-L...
10.
Hirano N, Nomura R, Tawara T, Tohyama K
J Comp Pathol
. 2003 Dec;
130(1):58-65.
PMID: 14693125
Mice aged 1, 4 or 8 weeks were inoculated with haemagglutinating encephalomyelitis virus (HEV), strain 67N, by the intracerebral (i.c.), intranasal (i.n.), intraperitoneal (i.p.), subcutaneous (s.c.), intravenous (i.v.) or oral...